Sustainability Impact of AstraZeneca’s US$50bn Investment
In 2023, the US invested US$96bn into the pharmaceutical industry, according to Statista.
There has been an increase in private spending on research and development (R&D) and approval of new drugs following a 50% increase from 2015-2019, according to the Congressional Budget Office, US.
The office continues to report that many new drugs are specialised for a small group of people, compared to the 1990s where low-cost drugs were being manufactured for the masses.
The AstraZeneca investment is its largest to date, US$50bn will contribute to growth for the US in the pharmaceutical industry.
Pascal Soriot, CEO, AstraZeneca, commenting on the results said: “As we enter our next phase of growth, we have pledged US$50bn to continue to grow in the US, which includes the largest manufacturing investment in AstraZeneca’s history, set for Virginia.
“This landmark investment reflects not only America’s importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca’s ambition to deliver US$80bn revenue by 2030.”
About AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnical company headquartered in Cambridge, UK.
The company operates on a large scale, selling medicine in more than 130 countries.
AstraZeneca says that its sustainability strategy focuses on the health of people, society and the planet.
Guiding its values to invest in people to create long-term value, resilience and trust, through operating ethically.
The company is decarbonising its operations and value chain with the sim to accelerate the delivery of net zero.
Pascal said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.
“It will also support our ambition to reach US$80bn in revenue by 2030.
“I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever.
“It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
How AstraZeneca is meeting its sustainability goals
In 2025 AstraZeneca updated its sustainability strategy which recognises the connection between business growth and the need to address major health challenges.
The company aims to reduce the carbon impact of pressurised metered dose inhalers using its innovative propellant aims to lower global warming potential by 99.9%, compared to current propellants.
The AstraZeneca Qure.ai partnership achieved five million chest X-rays for lung cancer in 20 countries, resulting in nearly 50,000 referrals for follow-up testing.
As well as the companies health equity initiative, Healthy Heart Africa created a national strategy for managing chronic kidney disease in Egypt.
"Today AstraZeneca announced its H1 and Q2 2025 results, and we saw strong momentum, with Total Revenue up 11% and remarkable pipeline delivery," says Pam Cheng, AstraZeneca's Chief Sustainability Officer and Executive Vice President - Global Operations & IT.
"I would like to recognise the more than 22,000 colleagues in Global Operations, IT and Sustainability for their exceptional contributions to our company’s performance in the first half of the year. Your dedication and passion for the patients we serve is inspiring.
"Looking ahead, we are excited about the future, as we continue to strengthen our manufacturing capabilities around the world – leveraging AI, automation and data analytics – to ensure that patients, wherever they are, receive the treatments they need, when they need them."
What will the US$50bn investment accomplish in Virginia?
The proposed project is a new multi-billion dollar drug substance manufacturing centre that is focused on chronic diseases, based in Virginia.
The facility will leverage AI, automation and data analytics that will optimise the production of small molecules, peptides and oligonucleotides.
Some of the drugs the company intends to produce are:
- oral GLP-1, a weight management drug that mimics the natural hormone released after eating
- Baxdrostat, which treats resistant hypertension, a condition where blood pressure remains high despite taking several medications
- oral PCSK9, is currently being developed to lower LDL cholesterol by inhibiting the PCSK9 protein
Governor Glenn Youngkin, Commonwealth of Virginia, said: “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States.
“This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain.
“Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
What are the other uses of the investment?
The billion dollar investment is intended to build on America’s global leadership in medicine manufacturing.
The investment that AstraZeneca plans to put into research and development and manufacturing across the US includes:
- Expansion of our R&D facility in Gaithersburg, Maryland
- State-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
- Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California
- Continuous manufacturing expansion in Mount Vernon, Indiana
- Specialty manufacturing expansion in Coppell, Texas
- New sites to supply clinical trials
- Growing research and development investment in novel medicines
The company hopes that these investments will deliver AstraZeneca's ambition of reaching US$80bn in total revenue by 2030.
Howard Lutnick, US Secretary of Commerce, said: “For decades Americans have been reliant on foreign supply of key pharmaceutical products.
“President Trump and our nation’s new tariff policies are focused on ending this structural weakness.
“We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.
“This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”
